Corline Biomedical AB
STO: CLBIO.ST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Stockholm Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Henrik Nittmar
- Employees
- 13
- Headquarters
- Uppsala, Sweden
- IPO year
- 2015
- Market cap
- SEK 448.2M
- Website
- https://www.corline.se
Loading CLBIO…
Loading profile data…Frequently asked questions about CLBIO
What does Corline Biomedical AB (CLBIO.ST) do?
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company's products include...
Where does CLBIO.ST trade?
Corline Biomedical AB (CLBIO.ST) trades on the Stockholm Stock Exchange.
What sector is CLBIO.ST in?
Corline Biomedical AB (CLBIO.ST) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Corline Biomedical AB?
Henrik Nittmar is the chief executive officer of Corline Biomedical AB (CLBIO.ST).
Where is Corline Biomedical AB headquartered?
Corline Biomedical AB is headquartered in Sweden.
Does CLBIO.ST pay a dividend?
Corline Biomedical AB (CLBIO.ST) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CLBIO.ST go public?
Corline Biomedical AB (CLBIO.ST) completed its initial public offering in 2015.